1. Academic Validation
  2. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

  • J Med Chem. 2017 Sep 14;60(17):7524-7538. doi: 10.1021/acs.jmedchem.7b00930.
Florent Beaufils 1 Natasa Cmiljanovic 1 Vladimir Cmiljanovic 1 Thomas Bohnacker 1 Anna Melone 1 Romina Marone 1 Eileen Jackson 1 Xuxiao Zhang 2 Alexander Sele 1 Chiara Borsari 1 Jürgen Mestan 3 Paul Hebeisen 3 Petra Hillmann 3 Bernd Giese 4 Marketa Zvelebil 1 Doriano Fabbro 3 Roger L Williams 2 Denise Rageot 1 Matthias P Wymann 1
Affiliations

Affiliations

  • 1 Department of Biomedicine, University of Basel , Mattenstrasse 28, 4058 Basel, Switzerland.
  • 2 MRC Laboratory of Molecular Biology , Francis Crick Avenue, Cambridge CB2 0QH, U.K.
  • 3 PIQUR Therapeutics AG , Hochbergerstrasse 60C, 4057 Basel, Switzerland.
  • 4 Department of Chemistry, University of Basel , St. Johanns-Ring 19, 4056 Basel, Switzerland.
Abstract

Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K Inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, Enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound's safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound 1 is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma.

Figures
Products